Hypertension Secondary Clinical Trial
Official title:
Relevance of the Ratio Kynurenine/Tryptophan to Characterize Hypertension Associated to Obstructive Sleep Apnea (KYNTOSA)
Obstructive Sleep Apnea (OSA) is an independent risk factor for hypertension (HTN) and the most common cause of resistant HTN. The mechanisms underlying OSA-associated HTN are not completely understood. This is crucial to find novel therapeutic targets of OSA-associated HTN. The Aryl Hydrocarbon Receptor (AHR) is a cytosolic transcription factor that has been linked with the pathogenesis of HTN. This study aims to evaluate the role of endogenous ligands of AHR such as kynurenine in discriminating patients with OSA-associated HTN. For that aim, a case-control study will be performed in patients with and without hypertension exposed and not exposed to OSA. Kynurenine and other metabolites will be quantified in urine and serum samples.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05539443 -
Telehealth-Enhanced Assessment and Management After Stroke-Blood Pressure
|
N/A | |
| Active, not recruiting |
NCT03753633 -
Efficiency of Speech Therapy in Resistant Hypertensive Patients With Mild Obstructive Sleep Apnea Syndrome
|
N/A | |
| Completed |
NCT03155139 -
Primary Aldosteronism In Hypertensive Patients in China
|
||
| Completed |
NCT03105531 -
Screening for Primary Aldosteronism in a Population of Patients With Hypertension
|
||
| Completed |
NCT03246022 -
Characteristics of Obstructive Sleep Apnea Syndrome Related Hypertension and the Effect of Continuous Positive Airway Pressure Treatment on Blood Pressure
|